NTLA compared with ARCT: revenue, margins and what each company keeps, and the suppliers and customers both name

NTLAIntellia Therapeutics, Inc.

Mkt capRevenueRevenue

ARCTArcturus Therapeutics Holdings Inc.

Mkt capRevenueRevenue

Compare

NTLAIntellia Therapeutics, Inc.

ARCTArcturus Therapeutics Holdings Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NTLA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±14.2%▼−9.83%×0.69

Q2 FY26±12.8%▲+2.46%×0.20

May 11 '26±7.2%▲+2.34%×0.32

Q1 FY26±18.7%▲+6.41%×0.34

ARCT

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.3%▲+10.58%×0.65

Q2 FY26±21.8%▲+21.88%×1.00

= impliedNTLA realized, solidARCT realized, hatchedOne scale, both sides: full bar = 22%× = |realized| ÷ impliedSource: market data

May 8 '26

±15.5%

▲+3.60%

×0.23

Q1 FY26±18.3%▼−4.17%×0.23

NTLAIntellia Therapeutics, Inc.

11.35▲+2.23%· post 11.31

Mkt cap$1.6BRevenue$7MQ3 FY26Revenue$68MFY25

ARCTArcturus Therapeutics Holdings Inc.

10.36▲+10.67%· post 10.36

ClosedNov 6 '26

Mkt cap$298.3MRevenue$18MQ3 FY26Revenue$82MFY25

Compare

ClosedNov 6 '26

NTLAIntellia Therapeutics, Inc.

ARCTArcturus Therapeutics Holdings Inc.

11.35▲+2.23%post 11.31

Price

10.36▲+10.67%post 10.36

$1.6B

Mkt cap

$298.3M

Q3 FY26$7M

Revenue

$18MQ3 FY26

FY25$68M

Revenue

$82MFY25

NTLA11.35▲+2.23%vsARCT10.36▲+10.67%ClosedNov 6 '26